Replies to post #810 on YM BioSciences Inc. (YMI)

[surf1944]

7:22AM YM BioSciences reports Q4 loss of ($0.04) vs $0.00 single estimate; revs rose 50% to 300K (no rev est) (YMI) 1.78 : Interim data from the extension trial, in which patients who have completed the 166 patient Phase I/II trial are able to continue long-term treatment with CYT387, are expected to be reported by the end of calendar 2012. Initial data from the Phase II BID trial are expected to be reported by the end of calendar 2012.